REVAC B

This brand name is authorized in Nigeria.

Active ingredients

The drug REVAC B contains one active pharmaceutical ingredient (API):

1	Hepatitis B, purified antigen UNII IFJ010MNE4 - HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN
	Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
	Read more about Hepatitis B, purified antigen

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-0147	Injection	REVAC B 1ML INJ 20mcg; 0.25mg 1 X 1ml	3 RNW-BV-305003 REVAC B 1ML HEPATITIS B SURFACE ANTIGEN 20MCG ,ALUMINUM HYDROXIDE GEL Aluminium hydroxide gel equivalent to Aluminium(Al+++) 0.25 mg Thiomersal BP Phosphate buffered saline A6-0147 Vaccines & Biologicals Biologics Imported Products 1X1ML 3/20/2023 PHILLIPS PHARMACEUTICALS (NIGERIA) LIMITED, PLOT 122-123 AFRIPRINT ESTATE, ISOLO 8035493198 samson.omattah@phillipsnigeria.com BHARAT BIOTECH INTERTIONAL LIMITED , SY NO 230 231 235 GENOMEVALLEY TELANGANASTATE INDIA TURKAPALLY( V)SHAMIRPET MEDCHAL -MALAJGIRI DIST ,500078., India	23/08/2023
A6-0456	Injection	REVAC B INJ 20 mcg/mL `110	REVAC B HEPATITIS B VACCINE (RDNA) B VIAL A6-0456 Vaccines & Biologicals Human Vaccines Imported Products `110 20/03/2023 PHILLIPS PHARMACEUTICALS (NIGERIA) LIMITED, PLOT 122-123 AFRIPRINT ESTATE, ISOLO 8035493198 samson.omattah@phillipsnigeria.com BHARAT BIOTECH INTERTIONAL LIMITED , SY NO 230 231 235 GENOMEVALLEY TELANGANASTATE INDIA TURKAPALLY( V)SHAMIRPET MEDCHAL -MALAJGIRI DIST ,500078., India	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BC01	Hepatitis B, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-0147, A6-0456